Respirerx Pharmaceuticals Inc (RSPI) Return on Equity ROE from the second quarter 2023 to second quarter 2022 and annually, average high and low, overall ranking from Jun 30 2023 to Jun 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Respirerx Pharmaceuticals Inc   (RSPI)

Respirerx Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Respirerx Pharmaceuticals Inc in the second quarter 2023?
Due to the lack of equity, it was not possible to calculate Respirerx Pharmaceuticals Inc 's return on equity (ROE) in its second quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -3 -4 -4 -4 -3
Return On Equity (TTM) - - - - -
RSPI's Total Ranking # # # # #
Equity (TTM) in Millions -12 -12 -12 -12 -11
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to RSPI Management Effectiveness >> RSPI's 5 Years Annual ROE >> Compare RSPI ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





RSPI Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018
Total Equity in Millions -12 -10 -8 -7 -6
Y / Y Equity Change - - - - -
Net Income in Millions -4 -3 -4 -2 -3
Y / Y Net Income Change - - - - -
Return On Equity - - - - -

Back to RSPI Management Effectiveness >> RSPI's 5 Years Annual ROE >> Compare RSPI ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RSPI's' Return on Equity at Yahoo Finance
RSPI's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RSPI's Competitors
Subscribers only: Roe for Respirerx Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for RSPI's Customers




Companies with similar Return On Equity at Jun 30 2023, within Healthcare Sector ROE
Davita Inc   74.49 %
Medpace Holdings Inc   72.88 %
Chimerix Inc   72.53 %
Dariohealth Corp   71.65 %
Voyager Therapeutics Inc   69.09 %
Vaso Corporation  63.88 %
Eli Lilly And Company  59.90 %
Kiniksa Pharmaceuticals International Plc  58.48 %
Abbvie Inc   58.42 %
Gyre Therapeutics Inc   56.24 %
Star Equity Holdings Inc   54.61 %
Opus Genetics Inc   54.45 %
Zoetis Inc   48.61 %
Harmony Biosciences Holdings inc   47.82 %
Shockwave Medical Inc   47.48 %
Zymeworks Inc   46.66 %
Enzo Biochem Inc  46.32 %
Assertio Holdings inc   45.16 %
Cv Sciences Inc   45.08 %
Tenet Healthcare Corp  44.05 %
Entera Bio Ltd   40.98 %
Tao Synergies Inc   40.31 %
Nrc Health  39.94 %
Revelation Biosciences Inc   37.76 %
Catalyst Pharmaceuticals Inc   36.13 %
Tenax Therapeutics Inc   35.84 %
Exicure Inc   34.49 %
Innoviva Inc   33.94 %
Pro dex Inc   33.92 %
Denali Therapeutics Inc   32.16 %

Date modified: 2026-09-08T15:11:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.